Genetic profile and cancer-related pain: A tale from two outlier cases with bone metastatic disease

Pain Medicine (United States)

Volumn 15, Issue 4, 2014, Pages 710-712

  Oliveira, Ana ^a,c,d   Dinis Oliveira, Ricardo Jorge ^a,b,d,e   Nogueira, Augusto ^c   Azevedo, Andreia S ^c   Gonçalves, Ferraz ^c   Silva, Paula ^c   Carvalho, Félix ^a   Medeiros, Rui ^a,c,f,g  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^e CESPU   (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^g LPCC   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DIAZEPAM; GABAPENTIN; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PREDNISOLONE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; COMT PROTEIN, HUMAN; GLUCURONOSYLTRANSFERASE; NARCOTIC ANALGESIC AGENT; OPRM1 PROTEIN, HUMAN; UGT2B7 PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; ALLELE; ANALGESIA; BONE METASTASIS; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CASE REPORT; FEMALE; FUNCTIONAL STATUS; GENE EXPRESSION PROFILING; GENETIC DIFFERENCE; GENOTYPE; HUMAN; LETTER; MALE; MIDDLE AGED; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE PAIN; SINGLE NUCLEOTIDE POLYMORPHISM; BONE TUMOR; GENETICS; METABOLIC ACTIVATION; METABOLISM; NEURALGIA; OSTEOSARCOMA; PATHOLOGY; PROSTATE TUMOR; SECONDARY; YOUNG ADULT;

ACTIVATION, METABOLIC; ANALGESICS, OPIOID; BONE NEOPLASMS; CATECHOL O-METHYLTRANSFERASE; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEURALGIA; NOCICEPTIVE PAIN; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, OPIOID, MU; YOUNG ADULT;

EID: 84898041413     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12314     Document Type: Letter

References (9)

1. Muralidharan A, Smith MT. Pain, analgesia and genetics. J Pharm Pharmacol 2011;63:1387-1400.
2. Meng QC, Soleded Cepeda M, Kramer T, etal. High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites by two-step solid-phase extraction. J Chromatogr B Biomed Sci Appl 2000;742:115-123.
3. Sia AT, Lim Y, Lim ECP, etal. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008;109:520-526.
4. Zubieta J-K, Heitzeg MM, Smith YR, etal. COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 2003;299:1240-1243.
5. Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT Val158Met polymorphism. PLoS ONE 2009;4:e6016.
6. Loggia ML, Jensen K, Gollub RL, etal. The catechol-O-methyltransferase (COMT) val158met polymorphism affects brain responses to repeated painful stimuli. PLoS ONE 2011;6:e27764.
7. Holthe M, Klepstad P, Zahlsen K, etal. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002;58:353-356.
8. Parmar S, Stingl JC, Huber-Wechselberger A, etal. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Res 2011;13:R57.
9. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997;41:116-122.